Literature DB >> 22727922

What change in the National Institutes of Health Stroke Scale should define neurologic deterioration in acute ischemic stroke?

James E Siegler1, Amelia K Boehme, Andre D Kumar, Michael A Gillette, Karen C Albright, Sheryl Martin-Schild.   

Abstract

BACKGROUND: Neurologic deterioration (ND) occurs in one-third of patients with stroke. However, the true incidence of ND and risk for adverse outcomes remains unknown because no standardized definition of ND exists. Our study compared the prognostic value of a range of definitions for ND in patients with acute ischemic stroke (AIS).
METHODS: All patients who presented to our center with AIS within 48 hours of symptom onset between July 2008 and June 2010 were retrospectively identified. Patient demographics, National Institutes of Health Stroke Scale (NIHSS) scores, etiologies of ND, and outcome measures were compared between patients according to a range of ND definitions using receiver operating characteristic analyses.
RESULTS: Three hundred forty-seven patients were included. The 2 definitions of ND with the highest sensitivity and specificity for several outcome measures were tested against each other: an increase in the NIHSS score by ≥2 or ≥4 points in a 24-hour period. More than one third (36.9%) of patients experienced ≥2-point ND versus 17.3% with ≥4-point ND. Patients who experienced ND by either definition had prolonged hospitalization (P < .001), poorer functional outcome (discharge modified Rankin Scale score >2; P < .001), and higher discharge NIHSS score (P < .001) compared to patients without ND. Compared to patients without ND, a ≥2-point ND was associated with a 3-fold risk of death (odds ratio 3.120; 95% confidence interval 1.231-7.905; P < .0165) after adjusting for admission NIHSS score, serum glucose, and age.
CONCLUSIONS: A ≥2-point ND is a sensitive indicator of poor outcome and in-hospital mortality. An accepted definition of ND is needed to systematically study and compare results across trials for ND in patients with stroke.
Copyright © 2013 National Stroke Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22727922      PMCID: PMC5535077          DOI: 10.1016/j.jstrokecerebrovasdis.2012.04.012

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  27 in total

1.  Cerebral vascular accidents in patients over the age of 60. II. Prognosis.

Authors:  J RANKIN
Journal:  Scott Med J       Date:  1957-05       Impact factor: 0.729

2.  Interobserver agreement for the assessment of handicap in stroke patients.

Authors:  J C van Swieten; P J Koudstaal; M C Visser; H J Schouten; J van Gijn
Journal:  Stroke       Date:  1988-05       Impact factor: 7.914

3.  NIH Stroke Scale reliability in ratings from a large sample of clinicians.

Authors:  S Andrew Josephson; Nancy K Hills; S Claiborne Johnston
Journal:  Cerebrovasc Dis       Date:  2006-08-04       Impact factor: 2.762

4.  Progression in acute stroke: value of the initial NIH stroke scale score on patient stratification in future trials.

Authors:  T J DeGraba; J M Hallenbeck; K D Pettigrew; A J Dutka; B J Kelly
Journal:  Stroke       Date:  1999-06       Impact factor: 7.914

5.  Neurologic worsening during the acute phase of ischemic stroke.

Authors:  Christian Weimar; Thomas Mieck; Joachim Buchthal; Christiane E Ehrenfeld; Elisabeth Schmid; Hans-Christoph Diener
Journal:  Arch Neurol       Date:  2005-03

6.  Poststroke neurological improvement within 7 days is associated with subsequent deterioration.

Authors:  Stella Aslanyan; Christopher J Weir; S Claiborne Johnston; Kennedy R Lees
Journal:  Stroke       Date:  2004-07-08       Impact factor: 7.914

7.  Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group.

Authors:  P Lyden; T Brott; B Tilley; K M Welch; E J Mascha; S Levine; E C Haley; J Grotta; J Marler
Journal:  Stroke       Date:  1994-11       Impact factor: 7.914

8.  Progressing stroke: towards an internationally agreed definition.

Authors:  Philip Birschel; John Ellul; David Barer
Journal:  Cerebrovasc Dis       Date:  2004-01-13       Impact factor: 2.762

9.  Measurements of acute cerebral infarction: lesion size by computed tomography.

Authors:  T Brott; J R Marler; C P Olinger; H P Adams; T Tomsick; W G Barsan; J Biller; R Eberle; V Hertzberg; M Walker
Journal:  Stroke       Date:  1989-07       Impact factor: 7.914

10.  Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.

Authors:  H P Adams; B H Bendixen; L J Kappelle; J Biller; B B Love; D L Gordon; E E Marsh
Journal:  Stroke       Date:  1993-01       Impact factor: 7.914

View more
  36 in total

Review 1.  Factoring in Factor VIII With Acute Ischemic Stroke.

Authors:  James E Siegler; Alyana Samai; Karen C Albright; Amelia K Boehme; Sheryl Martin-Schild
Journal:  Clin Appl Thromb Hemost       Date:  2015-02-10       Impact factor: 2.389

2.  Time to Neurological Deterioration in Ischemic Stroke.

Authors:  James E Siegler; Karen C Albright; Alexander J George; Amelia K Boehme; Michael A Gillette; Andre D Kumar; Monica Aswani; Sheryl Martin-Schild
Journal:  Med Student Res J       Date:  2017

3.  Acute decrease in serum magnesium level after ischemic stroke may not predict decrease in neurologic function.

Authors:  James E Siegler; Amelia K Boehme; Karen C Albright; Sami Bdeir; Anoop K Kar; Leann Myers; T Mark Beasley; Sheryl Martin-Schild
Journal:  J Stroke Cerebrovasc Dis       Date:  2013-07-04       Impact factor: 2.136

4.  Infections present on admission compared with hospital-acquired infections in acute ischemic stroke patients.

Authors:  Amelia K Boehme; Andre D Kumar; Adrianne M Dorsey; James E Siegler; Monica S Aswani; Michael J Lyerly; Dominique J Monlezun; Alexander J George; Karen C Albright; Timothy M Beasley; Sheryl Martin-Schild
Journal:  J Stroke Cerebrovasc Dis       Date:  2013-08-15       Impact factor: 2.136

5.  Persistent leukocytosis-is this a persistent problem for patients with acute ischemic stroke?

Authors:  Amelia K Boehme; Andre D Kumar; Michael J Lyerly; Michael A Gillette; James E Siegler; Karen C Albright; T Mark Beasley; Sheryl Martin-Schild
Journal:  J Stroke Cerebrovasc Dis       Date:  2014-04-29       Impact factor: 2.136

6.  Identification of modifiable and nonmodifiable risk factors for neurologic deterioration after acute ischemic stroke.

Authors:  James E Siegler; Amelia K Boehme; Andre D Kumar; Michael A Gillette; Karen C Albright; T Mark Beasley; Sheryl Martin-Schild
Journal:  J Stroke Cerebrovasc Dis       Date:  2012-12-16       Impact factor: 2.136

7.  Racial and gender differences in stroke severity, outcomes, and treatment in patients with acute ischemic stroke.

Authors:  Amelia K Boehme; James E Siegler; Michael T Mullen; Karen C Albright; Michael J Lyerly; Dominique J Monlezun; Erica M Jones; Rikki Tanner; Nicole R Gonzales; T Mark Beasley; James C Grotta; Sean I Savitz; Sheryl Martin-Schild
Journal:  J Stroke Cerebrovasc Dis       Date:  2014-01-25       Impact factor: 2.136

8.  Factor VIII in the setting of acute ischemic stroke among patients with suspected hypercoagulable state.

Authors:  Tiffany R Chang; Karen C Albright; Amelia K Boehme; Adrianne Dorsey; E Alton Sartor; Rebecca Kruse-Jarres; Cindy Leissinger; Sheryl Martin-Schild
Journal:  Clin Appl Thromb Hemost       Date:  2013-05-14       Impact factor: 2.389

9.  The Utility of Quantifiable Neurologic Assessments After Stroke: In response to Marsh et al, "The NIH Stroke Scale Has Limited Utility in Accurate Daily Monitoring of Neurologic Status".

Authors:  James E Siegler
Journal:  Neurohospitalist       Date:  2016-04-05

10.  A proposal for the classification of etiologies of neurologic deterioration after acute ischemic stroke.

Authors:  James E Siegler; Amelia K Boehme; Karen C Albright; Alexander J George; Dominique J Monlezun; T Mark Beasley; Sheryl Martin-Schild
Journal:  J Stroke Cerebrovasc Dis       Date:  2013-07-16       Impact factor: 2.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.